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Ex vivo characterization of Breg 
cells in patients with chronic 
Chagas disease
Magalí C. Girard1, Gonzalo R. Acevedo1, Micaela S. Ossowski1, Marisa Fernández2, 
Yolanda Hernández2, Raúl Chadi3 & Karina A. Gómez1*
Despite the growing importance of the regulatory function of B cells in many infectious diseases, 
their immunosuppressive role remains elusive in chronic Chagas disease (CCD). Here, we studied the 
proportion of different B cell subsets and their capacity to secrete IL-10 ex vivo in peripheral blood 
from patients with or without CCD cardiomyopathy. First, we immunophenotyped peripheral blood 
mononuclear cells from patients according to the expression of markers CD19, CD24, CD38 and CD27 
and we showed an expansion of total B cell and transitional  CD24highCD38high B cell subsets in CCD 
patients with cardiac involvement compared to non-infected donors. Although no differences were 
observed in the frequency of total IL-10 producing B cells (B10) among the groups, CCD patients with 
cardiac involvement showed an increased proportion of naïve B10 cells and a tendency to a higher 
frequency of transitional B10 cells compared to non-infected donors. Our research demonstrates 
that transitional B cells are greatly expanded in patients with the cardiac form of CCD and these cells 
retain the ability to secrete IL-10. These findings provide insight into the phenotypic distribution 
of regulatory B cells in CCD, an important step towards new strategies to prevent cardiomyopathy 
associated with T. cruzi infection.
Chagas disease, a serious health problem caused by the infection with the protozoan parasite Trypanosoma 
cruzi, comprises an acute and a chronic phase. During the latter, the disease may remain without any detectable 
symptoms for several decades, or progress toward cardiac or digestive pathological forms, or even a combination 
of these  alterations1. The absence of any symptoms, as well as the inflammatory mechanisms leading to tissue 
damage are attributed mainly to the immune response developed by the host against the parasite, and to the 
different means by which the parasite avoids it and persists. Although there is a bias towards a predominant pro-
inflammatory environment in cardiac patients, while an anti-inflammatory response would prevail in patients 
without clinical symptoms, data are not completely  conclusive2–4. In this context, the regulatory mechanisms 
that tend to return the immune response to a favorable equilibrium could play a relevant role in the context of 
Chagas disease.
Regulatory B (Breg) cells are a specific B cell subset allocated to restrain the excessive inflammatory response 
accomplished in different immune-related pathologies, such as autoimmune and allergic diseases, malignan-
cies, infections and solid organ  transplantation5,6. Through IL-10 production, Breg cells have the capacity to 
suppress the function and proliferation of Th1, Th17 and follicular helper T  (TFH) cells, increase polarization of 
T cells towards the regulatory T (Treg) cell profile, repress the innate response by acting on antigen-presenting 
cells (dendritic cells, macrophages) and natural killer (NK and NKT) cells, decrease the production of IgG 
while inducing class switch towards IgG4, among other  effects7. In addition, Breg cells have also been shown 
to contribute to immune homeostasis by IL-10-independent  mechanisms8. However, and due to the absence 
of subset-specific membrane markers or transcription factors, IL-10 secretion is still the hallmark feature used 
to distinguish Breg from the rest of the B  cells9,10. In humans, different B cell lineages that secrete this cytokine 
and have regulatory functions have been described, such as  CD19+CD24highCD38high11,  CD19+CD24highCD27+12, 
 CD19+CD5+CD1d+13,14,  CD19+Tim-1+15,16 and  CD19+CD25+CD71+CD73−  cells7, depending on the stimulation 
conditions and the markers used to identify them. Nowadays, the majority of the studies in human samples 
pinpoint the  CD19+CD24highCD38high, the phenotypic signature of the immature transitional B cell population, 
as the most representative of Breg  cells17.
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In the context of Chagas disease, B cells and their role as antibody secreting cells were amongst the first and 
most widely studied components of immunity against T. cruzi, but little is known about their relevance as antigen 
presenting cells, cytokine producers and immune  modulators3,18. To date, Fares et al. described that patients with 
chronic Chagas disease (CCD) have an increased frequency of IL-10- and TGF-β-producing B cells in peripheral 
blood, both in basal state and upon in vitro stimulation with parasite lysate, hinting that these cells participate 
in the delicate balance between protection and  pathogenesis19.
Given that Breg cells have the ability to ameliorate exacerbated inflammatory responses, hampering the 
development of tissue damage while contributing to pathogen persistence, we sought to analyze ex vivo whether 
changes in the frequency or phenotypic distribution of B and B10 cells from peripheral blood are associated with 
clinical outcome of patients with CCD.
Participants and methods
Subjects included and blood sample collection. Venous blood from patients with CCD and from 
non-infected donors was drawn into EDTA anticoagulated tubes (BD Vacutainer). Serology for Chagas’ disease 
was determined by indirect immunofluorescence, enzyme-linked immunosorbent assay (ELISA) or indirect 
hemagglutination; subjects who had at least two of three positive tests were considered to be infected. After a 
complete clinical and cardiologic examination covering medical history, physical examination, electrocardio-
gram (ECG), chest radiography, and echocardiophaphy, patients were stratified according to a modified version 
of the Kuschnir  classification20 as follow: Group 0, patients without demonstrable cardiac pathology (G0, n = 10) 
and Group 1, patients with cardiac involvement (G1, n = 10). Subjects in Group 0 (Kuschnir 0 or K0) had a 
normal ECG and normal chest radiography, whereas individuals within Group 1 had cardiac alterations such as 
right and/or left branch blockage and different degrees of conductive functional alterations (Kuschnir 1 or K1, 
n = 8), left ventricle enlargement (Kuschnir 2 or K2, n = 1) or heart failure symptoms (Kuschnir 3 or K3, n = 1). 
Because of sample availability reasons, most of the donors included in the G1 belonged to K1 stage. A random 
group of non-infected donors with negative serology for T. cruzi infection were included as the control group 
(NI, n = 9). The three groups were age- and gender-matched and their clinical features are detailed in Table 1. 
The exclusion criteria included record of history of treatment with benznidazole or nifurtimox and presence 
of systemic arterial hypertension, diabetes mellitus, thyroid dysfunction, renal insufficiency, chronic obstruc-
tive pulmonary disease, hydroelectrolytic disorders, alcoholism, history suggesting coronary artery obstruction, 
rheumatic disease, and the impossibility of undergoing the examinations.
An aliquot of whole blood (4 ml) from each participant was separated and centrifuged for 15 min at 800 g 
to obtain the plasma, which was stored at − 20 °C until use. The remainder of each sample was used to isolate 
peripheral blood mononuclear cells (PBMC), as described below. The titer of total anti -T. cruzi IgG antibodies 
in the plasma of patients was determined as previously  described21. For parasite load, total DNA was extracted 
from whole blood aliquots using the High Pure PCR Template Preparation kit (Roche Diagnostics Corp., Indiana, 
USA), following manufacturer-provided instructions.
Isolation and culture of PBMC. PBMC were isolated from whole blood by Ficoll-Hypaque density gra-
dient centrifugation (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) according to manufacturer-provided 
instructions, within 4 h after collection. Isolated PBMC were resuspended in fetal bovine serum (FBS, Natocor, 
Córdoba, Argentina) containing 10% dimethylsulphoxide and cryopreserved in liquid nitrogen until used. The 
number and viability of thawed PBMC were determined by Trypan blue exclusion staining and only samples 
with viability higher than 85% were used. Cell suspensions were seeded in 48-well flat-bottom plates at a density 
of 2 ×  106 cells/well in 500 µl of RPMI-1640 medium supplemented with 100 U/ml penicillin, 100 µg/ml strepto-
mycin, 2 mM l-glutamine and 10% heat-inactivated fetal bovine serum (FBS) at 37 °C in a humidified 5%  CO2 
incubator. After 18 h of culture, cells were incubated for additional 5 h with 50 ng/ml Phorbol-12-myristate-
13-acetate (PMA) (InvivoGen, San Diego, CA, USA) and 1 µg/ml Ionomycin (IONO) (MP Biomedicals, Santa 
Ana, CA, USA) or with culture medium only, in the presence of 5 µg/ml Brefeldin A (Biolegend, San Diego, CA, 
USA) (PIB) before being submitted to the flow cytometry staining process.
Flow cytometry staining. Cells were transferred to a 96-well V-bottom plate and washed once with PBS 
by centrifugation at 700 g for 3 min at room temperature (RT). Supernatants were discarded and cells were resus-
Table 1.  Demographic and clinical features of the study population. All patients and non-infected donors 
were age- and gender- matched and clinical features are detailed. The titer of total anti-T. cruzi IgG antibodies 
was consider as the  OD50 sera dilution factor. NA not applicable.
Characteristics NI (non T. cruzi-infected, n = 9)
G0 (CCD without cardiac involvement, 
n = 10) G1 (CCD with cardiac involvement, n = 10)
Age,median (interquartile range) 43 (36.5–60) 58 (51.5–61) 56.5 (51.7–64)
Gender, F/M 6/3 5/5 6/4
Kuschnir stage, 0–1–2–3 NA 10–0-0–0 0–8-1–1
PCR, +/− NA 0/10 1/9
Anti-T. cruzi IgG titer, median (interquartile 
range) 18 (7–31) 14,267 (5,635–42,503) 6,084 (2,070–20,049)
3
Vol.:(0123456789)
Scientific Reports |         (2021) 11:5511  | https://doi.org/10.1038/s41598-021-84765-x
www.nature.com/scientificreports/
pended in 25 µl of staining solution containing the antibodies detailed in Table 2, diluted in 1X live/dead fixable 
viability dye (Zombie-Aqua, Biolegend) and incubated 30 min at RT in the dark. After surface markers staining, 
cells were washed with PBS, fixed with Fixation Buffer (Biolegend) for 20 min at RT in the dark and washed with 
PBS by centrifugation at 700g for 3 min at RT. For intracellular IL-10 detection, cells were permeabilized with 
Perm-Wash Buffer (Biolegend), stained with anti-IL-10-PE antibody (Table 2) and fixed again with Fixation 
Buffer. “Fluorescence-minus-one” (FMO) controls were used to determine the cut point for the IL-10 staining, 
and isotype control staining was considered for cell surface markers gate setting. All antibodies were used at 
optimal concentrations determined by previous titration experiments. A minimum of 2 ×  105 events within the 
lymphocyte population were acquired in a FACSCanto II (BD Biosciences) flow cytometer using FACS Diva 
Software (BD Biosciences). Manual analysis of flow cytometry data was carried out with the program FlowJo 
version 10 (FlowJo LLC, Ashland, OR, USA). The gating strategy used to identify total lymphocytes population, 
B cells and B10 cells is detailed in Supplementary Figure S1 and subsequent gatings are described in each Figure.
Flow cytometry automated analysis. Flow cytometry automated analysis was performed by a den-
sity-based data clustering approach, called  flowPeaks22, implemented in R 3.6.123. Briefly, this method applies 
k-means clustering across the dimensions used for analysis to summarize the data, and finds density peaks in the 
distribution of the k-means clusters centroids. Next, the clusters are assigned to the density peak their centroid 
belongs to, and individual events are tagged with the ID of the peak they fall into. Flow data were filtered within 
each acquisition batch with flowPeaks, using the scatter parameters, markers CD3 and CD19, and the viability 
dye, to remove debris, non-viable cells, non-single cells and non-B cell events. After that, normalization across 
experimental batches was performed using the warp method from the flowStats  package24. Finally, the filtered 
and normalized data were pooled into a single matrix, and flowPeaks was applied to it in order to detect B cell 
subsets with differential expression of markers CD19, CD24, CD27 and CD38. B10 cells were identified using a 
hard threshold, derived from a density minimum on the distribution of IL-10 expression.
Statistical analysis. To analyze the differences in frequency of cell populations among groups we applied a 
generalized linear model (GLM) 25 with quasi-binomial distribution of errors and logit link function. Group and 
phenotype were considered fixed factors and the frequency of cells in each population was the dependent vari-
able. Mean fluorescence intensity data were analyzed by a linear regression model (LM) fitted by maximum like-
lihood. The group was set as the fixed factor and mean fluorescence intensity was the dependent variable. MFI 
data were tested for normality and homoscedasticity using Shapiro–Wilk and Bartlett tests, respectively. GLM 
and LM models were fitted in R 3.6.123. Results are represented with box and whiskers plots showing median 
value and interquartile ranges. P values less than 0.05 were considered statistically significant.
Ethics statement. The research protocols followed the tenets of the Declaration of Helsinki and were 
approved by the Medical Ethics Committee of Instituto Nacional de Parasitología “Dr. M. Fatala Chabén” and 
the Hospital General de Agudos “Dr. Ignacio Pirovano”. All enrolled patients and non-infected donors gave 
written informed consent, according to the guidelines of the Ethical Committee of each Institution, before blood 
collection and after the nature of the study was explained.
Results
Frequency of total and transitional B lymphocytes is altered in peripheral blood from patients 
with the cardiac form of chronic Chagas disease. In humans, four different subsets of periph-
eral blood B cells can be identified according to the expression levels of surface markers CD24 and CD38: 
 CD19+CD24highCD38high (immature transitional B cells),  CD19+CD24intCD38int (primarily mature naïve B cells), 
 CD19+CD24highCD38low (primarily memory B cells) and  CD19+CD24lowCD38high (plasmablasts)26,27. Since the 
combined expression of these markers has not been addressed in the context of chronic T. cruzi infection, we 
decided to evaluate the frequency of the subsets mentioned above within total  CD19+ B cells in PBMC from 
Table 2.  Fluorescent-labeled antibodies and isotype controls used for flow cytometry experiments.
Antibody/isotype control Clone Vendor
BV421-conjugated anti-CD3 UCHT1 Biolegend
PECy5-conjugated anti-CD4 RPA-T4 BD Biosciences
PECy5-conjugated anti-CD19 HIB19 BD Biosciences
APC-conjugated anti-CD27 M-T271 Biolegend
PECy7-conjugated anti-CD24 ML5 Biolegend
APCCy7-conjugated anti-CD38 HB-7 Biolegend
PE-conjugated anti-IL-10 JES3-9D7 Biolegend
BV421-mouse IgG1 ĸ MOPC-21 Biolegend
PECy5-mouse IgG1 ĸ MOPC-21 BD Biosciences
APC-mouse IgG1 ĸ MOPC-21 BD Biosciences
PECy7-mouse IgG 2a ĸ MOPC-173 Biolegend
APCCy7-mouse IgG1 ĸ MOPC-21 Biolegend
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CCD patients without cardiac compromise (G0, n = 10), CCD patients with cardiac involvement (G1, n = 10) 
and non-infected donors (NI, n = 9). First, we analyzed the frequency of total B lymphocytes and mean fluores-
cence intensity (MFI) for CD19 in the  CD19+ cell population. The gating strategy used to identify total B cells 
 (CD3−CD19+ cells) is illustrated in Supplementary Figure S1. Results revealed a higher percentage of  CD19+ B 
cells in patients with cardiac involvement compared to non-infected donors (p = 0.016; Fig. 1a). No statistically 
significant differences were observed between G0 and NI or between CCD groups. Furthermore, similar MFI 
levels were found across the cohort, independently of the clinical status of the subjects (Fig. 1b). Next, using the 
gating strategy represented in Fig. 1c, we quantified the frequencies of different B cell subsets according to CD24 
and CD38 expression in CCD patients and NI group. Results showed that the frequency of transitional B cells 
 (CD24highCD38high) within total B cells was higher in patients with cardiac involvement than in non-infected 
donors (p = 0.038). In addition, no significant differences were observed in the frequencies of the other B cell 
subpopulations among the groups (Fig. 1d).
We also determined the frequency of B cell subsets according to the expression of markers CD24 and CD27 
or CD27 and CD38. The gating strategy used to define each cell subset is illustrated for a representative donor 
in Fig. 2a,b. No differences among the groups were detected in any of the subpopulations evaluated (Fig. 2c,d).
Phenotypic distribution but not frequency of the B10 cell compartment is changed in periph-
eral blood from patients with the cardiac form of CCD. Since the  CD24highCD38high transitional B 
cell population has been associated with IL-10-mediated, regulatory B cell functions in human autoimmune and 
infectious  diseases11,28,29, we next studied IL-10 producing B cells (B10 cells) in peripheral blood from patients 
with the different clinical forms of CCD. We assessed the frequency of total B10 cells and B10 cell subsets accord-
ing to CD24, CD38 and CD27  expression11,29. The gating strategy is shown in Supplementary Figure S1 and 
Fig. 3a. Results showed that G1 patients have a tendency, although non-statistically significant, to a decreased 
frequency of B10 cells compared to non-infected donors (Fig. 3b). Furthermore, no differences in MFI of IL-10 
in IL-10+ B cells were observed among the groups (Fig. 3c).
The analysis of phenotypic distribution of B10 cells revealed that in G1 patients the frequencies of B10 cells 
with transitional and naïve phenotype were higher compared to those from NI donors (Fig. 3d). However, only 
the frequency of naïve B10 cells was statistically different among the groups (p = 0.036; Fig. 3e). This augmenta-
tion was related to a decrease in the frequency of B10 cells with memory phenotype in G1 patients (Fig. 3e). In 
fact, when we analyzed the ratio between both subpopulations in this group, we observed a shift towards naïve 
B10 cells that was undetectable in G0 patients and in non-infected individuals (ratio naïve/memory B10 cells 
in G1 = 0.98; G0 = 0.46; NI = 0.42).
Since CD27 is a memory marker of human B  cells30, we evaluated the frequency of B10 cells according to 
CD27 expression alone and in combination with CD24 and CD38. Results showed that B10 cells were mainly 
found in the  CD27+ (memory) population in the non-infected group, as it had been reported in blood samples 
from healthy  donors29 and the same pattern was observed in CCD patients (Fig. 4a,b). In addition, there were no 
differences in the frequency of memory  (CD27+) and naïve  (CD27−) B10 cells subsets among the groups (Fig. 4b).
Analysis of B10 cells subsets according to their CD24–CD27 expression showed an enrichment in 
 CD24−CD27− cells in G1 compared to G0 and NI donors (p = 0.039 and p = 0.027 respectively; Fig. 4c,d). Fre-
quencies of B10 cell subsets according to CD27–CD38 expression did not shown statistically significant differ-
ences among the groups (Fig. 4e,f).
Given that IL-10 producing B cells are not confined to a single B cell subset, several studies have tried to 
determine which B cell populations are enriched in IL-10+ cells. In this sense, most of the studies performed in 
human samples show that  CD24highCD38high and  CD24highCD27+ compartments exhibit higher frequencies of 
IL-10 producing cells than their respective  counterparts11,12,29. Taking this into account, we aimed to evaluate 
the frequency of IL-10+ cells within  CD24highCD38high and  CD24highCD27+ enriched subpopulations (Fig. 5a,b, 
respectively). With this approach, we did not find differences between the groups (Fig. 5c,d, respectively).
Data-driven clustering of B and B10 cells. Next, we applied an unsupervised clustering based approach 
to characterize in a multiparametric manner, event distributions within B and B10 cells in the context of CCD, 
and to evaluate the existence of subpopulations that cannot be easily identified by manual gating analysis. For this 
purpose, we used the flowPeaks  method22, an automated, density-based and data-oriented clustering approach. 
We identified five B cell clusters (“peaks”) based on the expression of CD19, CD24, CD27 and CD38, being the 
latter the marker with the most diverging expression profiles among B these cell subpopulations (Fig. 6a). Con-
versely, no differences were observed in the expression distribution of CD19 (Fig. 6a,b). Analyzing the features of 
each cluster, we observed that the peak 1 displayed an intermediate expression level of CD24, CD27 and CD38. 
Peaks 2 and 3 revealed high expression of CD27, but peak 2 had higher CD24 and lower CD38 levels than peak 
3. Peak 4 and especially peak 5 expressed the highest levels of CD24 and CD38. Furthermore, CD27 levels were 
low in peak 4 and intermediate in peak 5 (Fig. 6a,b).
When we compared the subpopulations identified using flowPeaks with those designated by manual gating, 
we observed that the region where conventional transitional B cells are located by CD24 and CD38 expression, 
was populated with cells assigned to peaks 1, 4 and 5. In addition, peak 4 and 5 partially overlapped in non-
infected subjects and G0 patients, while G1 patients displayed a spreading of peak 5 into a region of higher CD24 
and CD38 expression. The manually gated memory B cell population was mostly represented within peak 2, 
expressing the characteristic high level of CD27 and CD24 and low expression of CD38. Finally, the manually 
defined mature naïve B cell population was mainly composed by the events corresponding to peak 3 but also 
peaks 1 and 4 (Fig. 6c). Memory  CD24highCD27+ B cell subset by manual gating analysis was enclosed within 
peaks 1, 2, 3 and 5 (Fig. 6c). Next, we analyzed the frequencies of flowPeaks-gated subsets, but no statistically 
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Figure 1.  Frequency and phenotypic distribution of total B cells in peripheral blood from chronic Chagas 
patients and non-infected donors according to CD24 and CD38 expression. (a,b) Frequency of B cells 
 (CD3−CD19+) and mean level of CD19 expression (as mean fluorescence intensity; MFI) in the  CD3−CD19+ 
population from CCD patients (G0, G1) and non-infected donors (NI). (c) Representative dot plots from CCD 
patients and one non-infected donor, showing the gating strategy used to identify B cell subsets. According 
to CD24 and CD38 expression levels, B cells were sub-gated into:  CD19+  CD24highCD38high (immature 
transitional B cells),  CD19+CD24intCD38int (mature naïve B cells),  CD19+CD24highCD38− (memory B cells), 
 CD19+CD24lowCD38high (plasmablasts). (d) Frequency of different B cell subsets in total B cells from CCD 
patients (G0, G1) and non-infected donors (NI). Each dot represents data from one subject; inside G1 group, 
solid circles correspond to K1 patients, hollow triangle to K2 patient and hollow square to K3 patient. Boxes and 
whiskers show median value and interquartile range. Statistically significant differences among the groups are 
indicated (*p < 0.05).
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significant differences were found among the groups (Fig. 6d). In addition, peaks 2, 3 and 5 were enriched in 
B10 cells in all groups (Fig. 6e).
The flowPeaks method was also applied on pre-gated B10 cells, in order to evaluate their phenotypic distribu-
tion in terms of the aforementioned markers. Results showed five different density peaks in the data, although 
two of them contained too few events to sustain any ulterior analysis. Of note, peaks 1–5 from this analysis were 
not related in any way to peaks 1–5 from the bulk B cell analysis presented in Fig. 6, as they originated from 
independently run analyses. In the B10 cell subset analysis, peak 1 was characterized by intermediate expression 
of CD24, CD38 and CD27. Peak 2 included B10 cells with slightly higher levels of CD24 and CD27 but reduced 
levels of CD38 expression compared to peak 1. Finally, peak 3 contained B10 cells with low levels of CD24 and 
CD38 but intermediate levels of CD27 (Fig. 7a). Data analysis within each group showed that frequency of B10 
cells in peak 1 was higher than B10 cells in peak 2 and 3 (p < 0.001; Fig. 7b,c). Comparing among groups, we 
found that peak 3 had a trend of higher frequency in G0 than G1 patients and non-infected subjects while no 
differences were observed in the frequency of peaks 1 and 2 (Fig. 7b,c).
Discussion
In this study, we characterized for the first time the ex vivo B cell compartment in patients with chronic 
Chagas disease with and without cardiac involvement, in terms of their grouping in immature transitional 
 (CD19+CD24highCD38high), primarily mature  (CD19+CD24intCD38int), primarily memory  (CD19+CD24highCD38−) 
B cells, and plasmablasts  (CD19+CD24−CD38high)26,27. We found that immature transitional peripheral blood 
B cells had higher frequencies in patients with cardiac involvement compared to non-infected subjects, and 
that this expansion could be conjoined with an increase in the percentage of total  CD19+ B cells. In a previous 
work, Fernandez et al.31 observed an augmentation in the frequency of  CD19+IgG+CD27−IgD− “double nega-
tive” memory and  CD19+IgM+CD27−IgD+ transitional/naïve B cells with a selective reduction of their classical 
memory  CD27+ counterparts. In addition, and contrariwise to our observation, the frequency of  CD19+ B cells 
in infected individuals was significantly lower compared to non-infected subjects. In this regard, and although 
it would be interesting to correlate our findings with those described therein, it should be noted that B cell 
subsets were designated based on different surface markers. Furthermore, the infected subjects in the cohort 
of the mentioned study were grouped together for the analysis, independently of their clinical status. However, 
both studies clearly depict an alteration in the peripheral B cell compartments of infected individuals during 
the chronic phase of Chagas disease with a predominance of intermediate forms between the immature and 
Figure 2.  Frequency of B cell subsets based on CD24 and CD27 or CD27 and CD38 markers expression in 
peripheral blood from CCD patients and non-infected donors. (a,b) Representative dot plots from a non-
infected donor showing the gating strategy used to determine the subsets within total B cells according to the 
combined expression of CD24 and CD27 or CD27 and CD38. (c,d) Frequency of B cell subsets in CCD patients 
(G0, G1) and non-infected donors (NI). Each dot represents data from one subject; inside G1 group, solid circles 
correspond to K1 patients, hollow triangle to K2 patient and hollow square to K3 patient. Boxes and whiskers 
show median value and interquartile range.
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Figure 3.  Frequency and phenotypic distribution of B10 cells according to CD24 and CD38 expression in 
peripheral blood from CCD patients and non-infected donors. (a) Representative dot plots showing the gating 
strategy used to determine the IL-10+ B cells (B10 cells) in PIB stimulated PBMC. Fluorescence minus one 
controls (FMO) were used to define the negative populations for each sample. (b,c) Frequency of B10 cells in 
total B cells and mean fluorescence intensity (MFI) for IL-10+ in B10 cells in CCD patients (G0, G1) and non-
infected donors (NI). (d) Representative dot plots showing the gating strategy used. IL-10 expressing B-cells 
(B10 cells) were gated according to subject- and condition-matched FMO control tubes and were further 
sub-gated using CD24 and CD38 to identify the phenotypical distribution of these populations. (e) Frequency 
distribution of B10 cells according to CD24 and CD38 expression in CCD patients (G0, G1) and non-infected 
donors (NI). Each dot represents data from one subject; inside G1 group, solid circles correspond to K1 patients, 
hollow triangle to K2 patient and hollow square to K3 patient. Boxes and whiskers show median value and 
interquartile range. Statistically significant differences among groups are indicated (*p < 0.05).
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mature phenotypes. The expansion of circulating immature transitional with a decrease in memory B cells is a 
phenomenon that could be due to genetically intrinsic B cell abnormalities as well as extrinsic cellular or molecu-
lar factors that regulate B cell  lymphopoiesis32. In some immunodeficient states and autoimmune processes, 
transitional B cell alterations are associated with high expression levels of the B-cell activating factor of the TNF 
family, BAFF or IL-727,33–37, both essential for these cells to outright their  development38–42. Interestingly, there 
are evidences that BAFF and myeloid cell derived factors are abundantly secreted early after T. cruzi infection, 
leading not only to interferences in the development of mature B cells but also to a self-reactive response through 
polyclonal  activation43–46. What´s more, the IL-7/IL-7R axis was found to be altered in CCD patients with severe 
 cardiomyopathy47. Although Albareda et al. pointed out the preeminent role of this cytokine in controlling T cell 
Figure 4.  Phenotypic distribution of B10 cells according to CD27, CD27-CD24 and CD27-CD38 expression in 
CCD patients and non-infected donors. (a) Histograms showing the gating strategy used to determine  CD27− 
(naïve) and  CD27+ (memory) populations within B10 cells in PIB stimulated PBMC. One representative non-
infected donor is illustrated. (b) Frequency of  CD27− and  CD27+ B10 cells in CCD patients (G0, G1) and non-
infected donors (NI). (c,d) Representative dot plots from a non-infected donor showing gating strategy used 
to determine the subsets within total B10 cells based on the combine expression of CD24 and CD27 or CD27 
and CD38 in PIB stimulated PBMC. (e,f) Frequency of B10 cell subsets within CD24-CD27 and CD27-CD38 
subpopulations in CCD patients (G0 G1) and non-infected donors (NI). Each dot represents data from one 
subject; inside G1 group, solid circles correspond to K1 patients, hollow triangle to K2 patient and hollow square 
to K3 patient. Boxes and whiskers show median value and interquartile range. Statistically significant differences 
among groups are indicated (*p < 0.05).
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Figure 5.  IL-10 producing cells within  CD24highCD38high transitional and  CD24highCD27+ memory B cell 
populations in CCD patients and non-infected donors. (a,b) Representative dot plots showing the gating 
strategy used to determine frequency of IL-10+ cells in  CD24highCD38high and  CD24highCD27+ B cells. (c,d) 
Frequencies of IL-10+ cells within transitional  (CD24highCD38high) and memory  (CD24highCD27+) compartments 
in CCD patients (G0, G1) and non-infected donors (NI). Each dot represents data from one subject; inside G1 
group, solid circles correspond to K1 patients, hollow triangle to K2 patient and hollow square to K3 patient. 
Boxes and whiskers show median value and interquartile range.
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Figure 6.  Automatic gating performed by flowPeaks algorithm of B cell subsets based on CD19, CD24, CD27 
and CD38 expression. (a) Violin plots show the distribution of the expression of each marker for each peak. (b) 
Spider plots display the median expression for each marker in the different peaks. One graph is shown for each 
group of CCD patients (G0, G1) and non-infected donors (NI). (c) Representative biaxial dot plots showing the 
distribution of peaks based on CD24-CD38, CD24-CD27 and CD27-CD38 expression. (d) Box plots showing 
the percentage of B cells within each peak in G0, G1 and NI groups. (e) Box plots indicate the percentage of B10 
cells within each peak in the G0, G1 and NI groups.
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Figure 7.  Automatic gating performed by flowPeaks algorithm of B10 cell subsets based on CD19, CD24, CD27 
and CD38 expression. (a) Spider plots display the median expression for each marker in the different peaks. 
(b) Representative biaxial dot plots showing the distribution of peaks within B10 cells based on CD24–CD38, 
CD24–CD27 and CD27–CD38 expression. (c) Box plots showing the percentage of cells within each peak in 
B10 cells in G0, G1 and NI groups.
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 homeostasis47, the augmentation of serum levels of IL-7 detected in patients with CCD could be directly linked 
to our observation in the B cell compartment.
Production of IL-10 is the ultimate feature of several defined B regulatory  phenotypes48, and the broadest 
phenotypic marker of human Breg cells described so  far49. Several subsets of IL-10-producing human B cells 
have been proposed in studies centered on different diseases, immunological contexts and stimulation condi-
tions. These phenotypes include  CD1d+CD5+13,14,50,51, Tim-1+15,16, immature transitional  CD24hiCD38hi11,48 and 
memory  CD24highCD27+12 B cells, the last two being regarded as the main IL-10  producers12,52.
Focusing on chronic infections, a potent immunosuppressive role has been reported for B10 cells, acting 
mainly onto antigen specific  CD8+ T  cells53. In HIV-infected children and adolescents, an increased frequency 
of circulating Breg cells induced by influenza immunization has been linked to a poor response to  vaccination54. 
In leishmaniasis, IL-10 secreted by  CD5+CD1d+ B cells polarized the Th cell response toward the Th2 phenotype, 
leading to susceptibility to infection with the parasite in BALB/c  mice55. In fact, incubation of human B cells with 
Leishmania infantum amastigotes induced IL-10 production by  CD24+CD27− B cells, which partially modulated 
INF-γ and TNF-α secretion by T  cells56. Although B10 cells are involved in the maintenance of homeostasis in 
the immune  system5,57, these findings highlight the importance of microorganism- triggered immunosuppres-
sive mechanisms that could favor their persistence and contribute to poor vaccine  response58,59. Nonetheless, 
and given the implications of uncontrolled inflammation in the context of Chagas disease, B10 cells are likely to 
contribute to the delicate balance between parasite clearance and inflammatory pathogenesis.
As mentioned above, the only prior research addressing the role of B10 cells in chronic Chagas disease 
was carried out by Fares et al.19. Therein, T. cruzi infected patients presented a slightly higher frequency of IL-
10-producing  CD19+CD1d+CD5+ cells compared to non-infected subjects. Here, we found that the frequency of 
B10 cells was similar among the groups, but their phenotypic distribution based on surface markers CD24 and 
CD38 was altered in patients with cardiac involvement. While no differences were observed in the frequency 
and phenotypic distribution of B10 cells between non-infected donors and patients without cardiac involve-
ment, those with cardiac manifestations had significantly larger naïve and immature transitional subpopula-
tions within B10 cells. This augmentation seems to be associated with a decrease tendency in the frequency of 
 CD24highCD38low memory B10 cells. In fact, we found a change in naïve/memory B10 cell ratio in patients with 
cardiac alterations, favoring the former phenotype. Naïve and memory B10 cells are thought to have different 
functions in autoimmune and infectious diseases in humans, and their IL-10 production depends on specific 
activation signals in a particular immunological environment. While naïve B cells IL-10 production requires 
CD40 engagement to prevent inflammatory responses and maintain immune homeostasis, memory B cells IL-10 
production cells activates by a combined TLR, BCR and CD40 signaling to resolve the adaptive pathogen-specific 
immune response and autoimmune disease  inflammation60. It is not surprising that patients in the severe form 
of the disease display a phenotype towards naïve B10 cells since their immunological status refers an activated 
immune status with an important autoimmune  component3,61.
Interestingly, although  CD24highCD27+ IL-10 producing cells seemed not to be altered, the percentage of 
 CD24−CD27− cells was also significantly increased in patients with cardiac manifestations. The functional fea-
tures of this subpopulation remain elusive and the relevance of this augmentation will be a matter of further 
investigation in our laboratory.
Furthermore, our data revealed no differences in IL-10 production by  CD24highCD38high and  CD24highCD27+ 
B cells among the individuals independently of their clinical status, suggesting that B cells from patients with 
cardiac involvement have a regulatory phenotype mainly due to an expansion of the  CD24highCD38high immature 
transitional compartment, independently of their capacity to secrete IL-10. In relation to this, it was established 
that the frequency of  CD24highCD38high B cells changes in different clinical scenarios. In autoimmune settings, 
such as primary Sjögren syndrome and systemic lupus erythematosus (SLE), the frequency of this subset was 
shown to increase compared to healthy controls, while in HIV infection, an important decrease was  noted62. 
Furthermore, a connection between  CD24highCD38high B cells and immune regulatory function was evident in 
the favorable clinical outcome of patients with chronic inflammatory and autoimmune  diseases63. In the context 
of CCD, our results suggest a relationship between the cardiac manifestation of the disease and alterations in 
the frequency of transitional B cells.
Chronic Chagas cardiomyopathy and dilated cardiomyopathy (DCM) have a similar structural disarrange-
ment that leads to ventricular dilatation, but the former is characterized by severe myocarditis and a dense fibrosis 
that surrounds each myocardial fiber or group of myocardial  fibers64. Conversely to our observation, Guo et al. 
showed that the frequency of  CD19+IL-10+ B cells in peripheral blood from DCM patients was higher than those 
from healthy individuals under the same stimulation conditions followed in our  study65. However, when stimu-
lated with CD40L and CpG, the percentage of  CD19+IL-10+ B cells diminished in DCM patients compared to a 
healthy control  group66. In addition, the frequency of  CD24highCD38high transitional B cells and  CD24highCD27+ B 
cells in DCM patients were comparable with that of healthy individuals, while IL-10 production by  CD24hiCD27+ 
B cells from DCM patients was decreased. Although the experimental conditions differ between our study and 
that by Jiao et al. 66 and this could account for the discrepancies seen in the populations mentioned above, we 
cannot rule out that these alterations may be linked to the histopathological findings ascribed to each disease.
Finally, we also applied an automatic clustering based approach to identify the main B and B10 cellular sub-
types from our multidimensional flow cytometry dataset. These unsupervised methods have been used previously 
with multidimensional flow cytometry data, allowing researchers to identify cell subsets, including characterized 
and novel subpopulations of B cells of unknown biological  significance62,67. In our study, analysis of the expres-
sion of CD19, CD24, CD38 and CD27 parameters was able to identify several subsets with features consistent 
with the conventional populations previously described in the literature, in the context of healthy or pathological 
state. Furthermore, flowPeaks had the ability to reveal different expression levels of the memory marker CD27 
enclosed within the transitional B cell subset. In fact, memory  CD24highCD27+ regulatory B cells appeared as a 
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heterogeneous population, which also included cells belonging to the transitional B cell compartment, express-
ing intermediate or high levels of CD27 as part of the events within peak 1  (CD27intCD24highCD38int), peak 2 
 (CD27highCD24highCD38low) and peak 3  (CD24lowCD38lowCD27high). Our data agree with a previous report by 
Simon et al. where several subsets of transitional B cells are described within the  CD24highCD38high population, 
including  CD27− transitional B cells and a population with an atypical activated memory phenotype, character-
ized by  CD27+  expression62. It is important to mention that in the aforementioned study, a panel included also 
CD21, CD32, IgM, IgD, CD5 and CD10 markers was used to distinguish transitional B cell subsets. Considering 
these findings, it would be interesting to elucidate which subset within the transitional B cells is augmented in 
patients with the cardiac form of CCD and whether it displays differential abilities to regulate T cell response. 
In addition, flowPeaks method showed that only patients with cardiac involvement displayed a spreading of 
the subset that expressed the highest levels of CD24 and CD38 to a region of augmented expression of both 
markers. Our analysis did not detect any statistically significant differences among the groups under study in 
the proportion of the B cell subsets identified. It should be acknowledged, however, that the continuous nature 
of the expression levels of surface markers like CD24 and CD38 on B cells, with no preeminent modes or peaks 
in their distributions, constrain the power of density-based algorithms like flowPeaks to discern distinct popu-
lations. Although this may be perceived as a limitation of this type of approach, it actually hints at a broader, 
conceptual issue in single-cell level analyses: as useful as it is to partition cell populations into subsets for their 
characterization, often times this compartmentalization fails to reflect the true heterogeneity of cell phenotypes 
and functional profiles. This is particularly evident in the case of B cells. Nonetheless, we cannot rule out that 
the non-statistically significant trends, like the one observed for the B10 cells clustered in peak 3, which seem 
to have an increased frequency in CCD patients, might become significant if a larger cohort is studied. On that 
note, increasing the statistical power of our assessment by raising the number of enrolled subjects in each group 
may result in other non-significant trends observed in the manual gating analysis of our dataset becoming sta-
tistically significant as well.
In summary, our work shows that immature transitional  CD24highCD38high B cells are greatly expanded in 
patients with the cardiac form of CCD, and that these cells keep the same capacity to secrete IL-10 compared 
to non-infected donors. Additionally, flowPeaks gating revealed that this augmentation could be related with 
an increase in CD24 and CD38 expression within transitional B cells. This expansion might be the result of 
defective B cell development during acute T. cruzi infection or could be the consequence of a pro-inflammatory 
state. Remarkably, the distribution of naïve, transitional and memory B cells inside the B10 cells follows the 
same pattern in chronic patients without cardiac involvement and non-infected individuals. Finally, our data 
are insufficient to define whether these immature transitional  CD24highCD38high B cells or some subset within 
this population have deficiencies in their regulatory function and correlate with the clinical outcome of patients 
with chronic Chagas disease. We expect that our ongoing in vitro studies aiming at the elucidation of the Breg 
cells’ impact on  CD4+ and  CD8+ T cells may help to address this matter.
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